Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus.

Saved in:
Bibliographic Details
Title: Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus.
Authors: Sathe AG; Center for Orphan Drug Research, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.; Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA., Mishra U; Center for Orphan Drug Research, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA., Ivaturi V; Center for Translational Medicine, University of Maryland, Baltimore, Maryland, USA., Brundage RC; Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA., Cloyd JC; Center for Orphan Drug Research, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.; Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA., Elm JJ; Department of Public Health Science, Medical University of South Carolina, Charleston, South Carolina, USA., Chamberlain JM; Division of Emergency Medicine, Children's National Hospital and the Department of Pediatrics and Emergency Medicine, School of Medicine and Health Sciences, George Washington University, Washington, District of Columbia, USA., Silbergleit R; Department of Emergency Medicine, University of Michigan, Ann Arbor, Michigan, USA., Kapur J; Department of Neurology and Department of Neuroscience, Brain Institute, University of Virginia, Charlottesville, Virginia, USA., Lowenstein DH; Department of Neurology, University of California, San Francisco, California, USA., Shinnar S; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA., Cock HR; Clinical Neurosciences Academic Group, Institute of Molecular and Clinical Sciences, St George's University of London, London, UK., Fountain NB; Department of Neurology, Comprehensive Epilepsy Program, Charlottesville, Virginia, USA., Babcock L; Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA., Coles LD; Center for Orphan Drug Research, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.; Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
Source: Journal of clinical pharmacology [J Clin Pharmacol] 2021 Jun; Vol. 61 (6), pp. 763-768. Date of Electronic Publication: 2021 Jan 12.
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
Journal Info: Publisher: Wiley Country of Publication: England NLM ID: 0366372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-4604 (Electronic) Linking ISSN: 00912700 NLM ISO Abbreviation: J Clin Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1552-4604
DOI:10.1002/jcph.1801